Syphilis - Primary References

REFERENCES

Trigg BG, Kerndt PR, Aynalem G. Sexually transmitted infections and pelvic inflammatory disease in women. Med Clin North Am. 2008 Sep;92(5):1083-1113. http://www.ncbi.nlm.nih.gov/pubmed/?term=18721654. Accessed 28 May 2010. PMID: 18721654
Harting M, Rosen T, Vandergriff T. Antibiotic use in sexually transmissible diseases. Dermatol Clin. 2009 Jan;27(1):49-61. doi: 10.1016/j.det.2008.07.002. PMID: 18984368
French P, Gomberg M, Janier M, et al. IUSTI: 2008 European guidelines on the management of syphilis. Int J STD AIDS. 2009 May;20(5):300-309. http://ijsa.rsmjournals.com. Accessed 28 May 2010. PMID: 19386965
French P, Goh G, Goold P, et al. UK national guidelines on the management of syphilis 2008. Int J STD AIDS. 2008 Nov;19(11):729-740. http://www.bashh.org/guidelines. Accessed 29 May 2010. PMID: 18931264
Mattei PL, Beachkofsky TM, Gilson RT, Wisco OJ. Syphilis: a reemerging infection. Am Fam Physician. 2012 Sep;86(5):433-440. PMID: 22963062
Ferri FF. Syphilis. In: Alvero R, Borkan JM, Dobbs MR, et al, eds. Ferri's Clinical Advisor: Instant Diagnosis and Treatment. 1st. Philadelphia: Mosby Inc, an affiliate of Elsevier; 2010.
MedWorm http://www.medworm.com/rss/index.php/Dermatology/12/ http://www.medworm.com/rss/medicalfeeds/specialities/Dermatology-News.xml
MedWormhttp://www.medworm.com/rss/index.php/OBGYN/29/http://www.medworm.com/rss/medicalfeeds/specialities/OBGYN.xml
World Health Organization. Guidelines for the management of sexually transmitted infections. WHO. http://www.who.int. 2003. Accessed 28 May 2010.
Canadian guideline on sexually transmitted infections: syphilis. Public Health Agency of Canada. http://www.phac-aspc.gc.ca. Accessed 28 May 2010.
Management of patients who have genital ulcers. Centers for Disease Control and Prevention. http://www.cdc.gov. Accessed 28 May 2010.
Management of genital ulcers & discharges (summary booklet). Ministry of Health Singapore. http://www.moh.gov.sg. May 2009. Accessed 31 May 2010.
Syphilis. The New Zealand Sexual Health Society (NZSHS). http://www.nzshs.org. Accessed 28 May 2010.
Syphilis-CDC fact sheet. Centers for Disease Control and Prevention. http://www.cdc.gov/std/syphilis/STDFact-Syphilis-detailed.htm. Feb 2013. Accessed 16 Jul 2013
Lazaro N. Sexually transmitted infections in primary care 2013 (RCGP/BASHH). Royal College of General Practitioners. http://www.rcgp.org.uk. 2013. Accessed 30 May 2014.
Kingston M, French P, Goh B, et al; Syphilis Guidelines Revision Group 2008, Clinical Effectiveness Group. UK national guidelines on the management of syphilis 2008. Int J STD AIDS. 19(11):729-740. doi: 10.1258/ijsa.2008.008279. PMID: 18931264
Ministry of Health Malaysia. National antibiotic guideline 2014, 2nd edition. Pharmaceutical Services Divisions, Ministry of Health Malaysia. http://www.pharmacy.gov.my. Dec 2014. Accessed 16 Jul 2015.
World Health Organization. WHO guidelines for the treatment of Treponema pallidum (syphilis). WHO. http://www.who.int. 2016. Accessed 08 Sep 2016.
Hook EW. Syphilis. Lancet. 2017 Apr 15;389(10078):1550-1557. http://dx.doi.org/10.1016/S0140-6736(16)32411-4.

SARS-CoV-2 Variants: Everything you need to know

01 Feb 2023

The COVID-19 pandemic continues to evolve with the emergence of new SARS-CoV-2 variants. The variants of concern have the potential to impact the transmissibility, virulence, and clinical presentation of the disease, affecting the epidemiology, public health measures, and diagnostic and therapeutic options. Mutations in the spike protein of the virus have increased its ability to infect humans and evade neutralization by natural or immunisation-induced antibodies. The highly mutated Omicron variant of SARS-CoV-2 has multiple sublineages with varying transmissibility and immune evasion potential. Pre-exposure prophylaxis plays a crucial role in protecting the immunocompromised populations against severe disease; however, the rapidly changing landscape of the variants poses a major challenge to the current and future effectiveness of pre-exposure prophylactic monoclonal antibodies.

Management of MDROs in the ICU and the role of newer antimicrobial agents

Prof. David Paterson, 30 Mar 2021

Intensive care unit (ICU) patients are at risk of developing serious infections with multidrug-resistant organisms (MDROs), which require appropriate and adequate antibiotic coverage. Early empirical coverage is pivotal in saving patients’ lives. At a recent webinar co-organized by the Society of Infectious Disease (Singapore) and Pfizer, renowned Professor David Paterson, Professor of Medicine and Director, The University of Queensland Centre for Clinical Research, and Consultant Infectious Diseases Physician, Royal Brisbane and Women’s Hospital, Brisbane, Australia, discussed the role of newer antimicrobial agents, including ceftazidime-avibactam (Zavicefta) in the management of MDROs in the ICU. Dr Wong Sin Yew, Infectious Disease Physician at Gleneagles Medical Centre and Mount Elizabeth Novena Specialist Centre, Singapore, chaired the event.

ID NOW rapid molecular assay an effective COVID-19 test for kids

Rapid COVID-19 testing: Is it as good in kids?

Roshini Claire Anthony, 20 Oct 2021

A large retrospective study from the US, presented at IDWeek 2021, has shown that the Abbott ID NOW rapid molecular COVID-19 assay is highly sensitive and specific at detecting SARS-CoV-2 infection in a paediatric population.